Cystatin C: Evidence-Based Ways to Improve This Number

What Cystatin C Actually Measures

Cystatin C is a cysteine protease inhibitor produced by every nucleated cell in your body at a near-constant rate. Unlike creatinine, its production does not depend on how much muscle you carry. That matters enormously for women, who on average have less skeletal muscle mass than men, meaning creatinine-based kidney estimates routinely overstate a woman's true kidney function.

Your kidneys filter Cystatin C freely through the glomerulus, then reabsorb and break it down in the tubules. If the filters slow down, Cystatin C builds up in the blood. The result is a cleaner signal of glomerular filtration rate (GFR) than creatinine provides.

Why Creatinine Misleads Women

A woman with low muscle mass, which is common in older age, malnutrition, or prolonged inactivity, can have a serum creatinine that looks completely normal even when her kidneys are working at 60 percent of expected capacity. Several studies have documented this phenomenon. One analysis found that creatinine-based eGFR overestimates measured GFR by a mean of 11 mL/min/1.73 m² in women with low muscle mass, a gap large enough to miss stage 3 CKD entirely.

The 2021 CKD-EPI Upgrade

The Chronic Kidney Disease Epidemiology Collaboration released a revised 2021 equation that removes race as a variable and adds Cystatin C as an optional second analyte. When both creatinine and Cystatin C are available, the combined equation reduces systematic bias substantially. The National Kidney Foundation and American Society of Nephrology now recommend ordering Cystatin C any time the creatinine-based estimate is uncertain or when therapeutic decisions hinge on the exact GFR.

Normal Cystatin C Range: What the Numbers Mean for You

Most clinical laboratories report a normal Cystatin C as below 1.0 mg/L, though reference intervals vary slightly by assay. The table below gives practical clinical anchors.

| Cystatin C (mg/L) | Interpretation | Typical CKD Stage Implication | |---|---|---| | <0.70 | Optimal | No CKD concern | | 0.70 to 0.99 | Normal | No CKD concern | | 1.00 to 1.24 | Mildly elevated | Warrants repeat + creatinine | | 1.25 to 1.74 | Moderately elevated | Consistent with CKD stage 3 | | >1.75 | Markedly elevated | CKD stage 4-5 range; nephrology referral |

These thresholds are derived from population studies referenced in the KDIGO 2022 CKD guidelines. Your individual result must always be interpreted alongside creatinine, urine albumin-to-creatinine ratio, blood pressure, and clinical history.

How Life Stage Shifts the Baseline

Cystatin C is not perfectly stable across a woman's life.

Reproductive years. Values are generally lowest and most stable here. Oral contraceptives containing estrogen modestly raise Cystatin C by approximately 7 to 10 percent, likely through hepatic effects on production rate rather than true GFR change. If you are on combined hormonal contraception and your Cystatin C comes back at 1.05 mg/L, that mild elevation may partly reflect the pill rather than kidney disease.

Pregnancy. GFR rises 40 to 65 percent in the first and second trimesters, so Cystatin C drops. By the third trimester, a combination of reduced GFR and increased cellular production causes Cystatin C to rise back toward or above pre-pregnancy values. Standard non-pregnant reference ranges do not apply in the third trimester. Preeclampsia causes a sharper rise; a Cystatin C above 1.0 mg/L in the second trimester has been studied as an early marker of preeclampsia risk, though it is not yet part of routine screening protocols per ACOG.

Perimenopause and menopause. Declining estrogen accelerates muscle loss and reduces renal plasma flow. Population data show Cystatin C rises by roughly 15 percent in the decade after menopause even when creatinine remains stable. This means post-menopausal women are more likely to have their kidney disease detected when Cystatin C is ordered alongside creatinine. If you are 50 or older and your creatinine looks fine but your clinician is concerned about kidney function, pushing for a Cystatin C is a reasonable ask.

What a High Cystatin C Means

A Cystatin C above 1.0 mg/L signals that your kidneys are clearing less of this protein per minute than expected. That slower clearance corresponds to a lower eGFR.

Causes to Rule Out First

Not all high readings represent true kidney dysfunction. Thyroid status is the most common confounder. Hypothyroidism raises Cystatin C independent of GFR because thyroid hormone regulates the rate of Cystatin C production. A woman whose TSH is 12 mIU/L will have a falsely elevated Cystatin C that normalizes once she is adequately treated with levothyroxine. Hyperthyroidism has the opposite effect, suppressing Cystatin C below true GFR.

Systemic inflammation also raises Cystatin C. Conditions common in women, including rheumatoid arthritis, lupus, and active inflammatory bowel disease, can raise the marker through increased production rather than reduced filtration.

Corticosteroids, including prednisone used for autoimmune conditions, raise Cystatin C production directly.

When High Truly Means CKD

Once thyroid status is normal and active inflammation is controlled, a persistently elevated Cystatin C confirmed on repeat testing at least 90 days apart meets the KDIGO 2022 chronicity criterion for CKD. The leading causes in women include diabetic kidney disease, hypertensive nephrosclerosis, lupus nephritis, and, less commonly, polycystic kidney disease.

What a Low Cystatin C Means

Low Cystatin C, generally below 0.60 mg/L, is rarely pathological. It may appear in hyperthyroidism, in women with very high skeletal muscle mass (which does not affect Cystatin C production), or simply reflect excellent kidney reserve. Some research suggests low Cystatin C is associated with better cardiovascular outcomes, though causality runs through better kidney function rather than Cystatin C itself being protective.

Evidence-Based Ways to Improve Your Cystatin C

Improving your Cystatin C means improving your glomerular filtration rate, reducing inflammation, and managing the conditions that accelerate kidney decline. The strategies below have the strongest evidence in women specifically or in mixed-sex populations where female-specific data exist.

1. Control Blood Pressure Aggressively

Blood pressure is the strongest modifiable driver of Cystatin C trajectory. The SPRINT trial showed that targeting systolic blood pressure below 120 mmHg, compared with below 140 mmHg, reduced cardiovascular events and slowed kidney function decline. Women comprised 35 percent of participants; the benefit direction was consistent.

For women with CKD and proteinuria, KDIGO 2022 recommends a target below 120 mmHg systolic when tolerated. ACE inhibitors and ARBs are first-line because they reduce intraglomerular pressure independently of systemic blood pressure reduction.

Practical actions:

• Aim for home blood-pressure readings consistently below 130/80 mmHg.
• Reduce sodium to less than 2 g per day, which is roughly 5 g of table salt.
• Each 10 mmHg reduction in systolic pressure over two years may correspond to a measurable slowing in Cystatin C rise, based on SPRINT subgroup data.

2. Manage Blood Sugar and Insulin Resistance

Hyperglycemia damages the glomerular filtration barrier through multiple mechanisms, including advanced glycation end products and hemodynamic changes. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce kidney disease progression in people with type 2 diabetes and CKD, with effects documented through Cystatin C-based eGFR in secondary analyses of the CREDENCE trial.

For women with PCOS, insulin resistance raises Cystatin C through two pathways. First, hyperinsulinemia promotes systemic inflammation, which increases Cystatin C production. Second, metabolic hypertension in PCOS accelerates glomerular damage. A 2019 meta-analysis found women with PCOS had significantly higher Cystatin C levels than age-matched controls, even after adjusting for BMI. Metformin improved Cystatin C in some of these cohorts, though the data are not yet definitive enough to recommend it solely for this purpose.

3. Adopt a Kidney-Protective Eating Pattern

Diet influences Cystatin C through blood pressure, inflammation, and acid-base balance. Chronic dietary acid load, driven by high animal-protein intake, accelerates tubulointerstitial injury.

What the evidence supports:

• DASH diet. Randomized data show DASH reduces blood pressure by 8 to 14 mmHg systolic, which over years translates to slower kidney decline.
• Plant-forward protein. Replacing 50 percent of animal protein with plant protein reduces dietary acid load and slows eGFR decline in CKD patients by a mean of 1.08 mL/min/1.73 m² per year. That is modest but cumulative.
• Sodium restriction. Already noted under blood pressure, but worth restating: processed food is the dominant sodium source for most women, contributing up to 77 percent of daily intake.
• Potassium adequacy. Most women consume far less than the recommended 2,600 mg per day. Potassium blunts sodium's pressor effect and has independent kidney-protective properties. Beans, lentils, leafy greens, and avocado are practical sources. Exception: if your Cystatin C reflects true CKD stage 3b or higher, potassium intake requires monitoring with your nephrologist because clearance may be impaired.

What to limit:

• Ultra-processed foods: these carry phosphate additives that worsen CKD progression.
• Chronic NSAID use: ibuprofen and naproxen reduce renal prostaglandin synthesis and can raise Cystatin C reversibly within days of regular use. Acetaminophen is the preferred over-the-counter analgesic for women with borderline kidney function.

4. Exercise Regularly, but Match Intensity to Your Stage

Aerobic exercise improves endothelial function, lowers blood pressure, and reduces insulin resistance, all of which benefit Cystatin C. A 2021 meta-analysis in the American Journal of Kidney Diseases found that structured aerobic exercise improved eGFR by a mean of 3.1 mL/min/1.73 m² in CKD patients over 12 to 24 weeks.

For perimenopausal and post-menopausal women, resistance training is especially relevant. Preserving muscle mass counters the sarcopenia-driven drop in creatinine that can mask declining kidney function, and resistance exercise improves insulin sensitivity independently.

Aim for 150 minutes per week of moderate-intensity aerobic activity plus two sessions of resistance training, per CDC physical activity guidelines. Vigorous exercise acutely raises creatinine (not Cystatin C), so Cystatin C-based eGFR is more stable around workout timing.

5. Treat Thyroid Disease to Target

Because hypothyroidism directly raises Cystatin C through increased production, getting your TSH into the normal range may lower your Cystatin C without any actual change in kidney filtration. The magnitude is approximately 0.1 to 0.2 mg/L reduction per normalized TSH unit based on observational data, though the dose-response is not linear.

For women on levothyroxine for Hashimoto thyroiditis or post-thyroidectomy, maintaining TSH between 0.5 and 2.5 mIU/L optimizes Cystatin C interpretation and general metabolic health. If your Cystatin C is elevated and you have untreated or undertreated hypothyroidism, treat the thyroid first, then recheck Cystatin C at three months.

6. Reduce Chronic Inflammation

For women, inflammatory conditions that raise Cystatin C disproportionately include lupus, rheumatoid arthritis, endometriosis-associated immune activation, and postpartum thyroiditis. A practical framework: if your Cystatin C is elevated but your creatinine and urine albumin are normal, and you carry one of these diagnoses, quantify the inflammatory load with hsCRP and ESR before attributing the high Cystatin C to the kidneys alone.

Strategies with evidence:

• Treat the underlying condition. Disease-modifying therapy for lupus (hydroxychloroquine) lowers Cystatin C in parallel with CRP reduction in published cohort studies.
• Anti-inflammatory dietary pattern. A Mediterranean-style diet reduces hsCRP by roughly 20 percent in randomized trials, with secondary benefits on blood pressure and insulin sensitivity.
• Adequate sleep. Chronic sleep restriction raises IL-6 and CRP. Women average worse sleep quality than men across the lifespan, with a second nadir during perimenopause. Addressing vasomotor symptoms that fragment sleep may have downstream kidney health benefits, though direct Cystatin C data are not yet available.

7. Review Medications That Affect Cystatin C

Several drugs change Cystatin C outside of true GFR change.

| Drug / Class | Effect on Cystatin C | Mechanism | |---|---|---| | Corticosteroids | Raises by 15 to 20 percent | Increases production rate | | Combined oral contraceptives | Raises by 7 to 10 percent | Hepatic induction | | Cyclosporine / tacrolimus | Raises | Both nephrotoxic and production effects | | Thyroid hormone (T4) | Lowers when hyperthyroid | Reduces production rate | | SGLT2 inhibitors | Acute slight rise then long-term stabilization | Hemodynamic; tubuloglomerular feedback |

If you are on any of these medications and your Cystatin C is flagged, tell your clinician before any dose change or diagnostic workup is initiated for kidney disease.

Cystatin C and Specific Women's Health Conditions

PCOS and Metabolic Syndrome

Women with PCOS have a two- to threefold higher prevalence of CKD risk factors than age-matched controls, driven by insulin resistance, hypertension, and chronic low-grade inflammation. Cystatin C is a more sensitive early marker in this group than creatinine because many women with PCOS have lower-than-average muscle mass relative to body fat. Screening Cystatin C annually alongside urine albumin makes sense once a woman with PCOS crosses 35 or has had hypertension or prediabetes for more than three years.

Menopause and Hormone Therapy

Post-menopausal women lose roughly 0.5 to 1 percent of GFR per year beyond the baseline aging rate due to estrogen withdrawal effects on renal vasodilation. Observational data suggest estrogen has kidney-protective hemodynamic properties, but randomized trial data (WHI) did not show a clear GFR benefit from oral conjugated estrogen, possibly because oral estrogen raises angiotensinogen and blood pressure in some women.

Transdermal estradiol avoids the hepatic first-pass effect and may be neutral or mildly beneficial for blood pressure. The Menopause Society 2023 position statement supports individualized hormone therapy decisions; kidney protection is not currently a primary indication, but the absence of harm in low-risk women with recent menopause is reassuring.

Lupus Nephritis

Lupus nephritis affects women at a 9:1 ratio compared with men and is a leading cause of CKD in women under 50. Cystatin C tracks lupus nephritis activity better than creatinine in flares because creatinine often lags. If you have lupus and your Cystatin C rises above 1.0 mg/L with stable creatinine, treat it as a sentinel signal for early nephritis activity and request a 24-hour urine protein or urine protein-to-creatinine ratio.

Pregnancy and Cystatin C: What You Need to Know

Pregnancy transforms kidney physiology. GFR rises by 40 to 65 percent by the end of the first trimester, driven by increased cardiac output and renal plasma flow. This means Cystatin C drops meaningfully in the first and early second trimesters, and any result from that window should be compared against pregnancy-specific reference ranges, not standard adult values.

By the third trimester, Cystatin C rises back toward baseline or slightly above it. This normal gestational pattern can be confused with kidney deterioration if the clinician is not aware of trimester-specific norms.

Preeclampsia. Elevated Cystatin C in the second trimester has been evaluated as an early preeclampsia predictor in several prospective cohorts. A 2012 meta-analysis found that second-trimester Cystatin C above 0.74 mg/L was associated with a significantly increased risk of subsequent preeclampsia, though sensitivity and specificity remain insufficient for routine screening per current ACOG practice bulletins.

What to do if your Cystatin C is high during pregnancy. Do not panic at a third-trimester elevation below 1.2 mg/L without accompanying proteinuria or hypertension. If you have both an elevated Cystatin C and new hypertension or proteinuria, that combination warrants urgent obstetric evaluation.

Medications during pregnancy. ACE inhibitors and ARBs, the first-line drugs for CKD management outside pregnancy, are contraindicated in the second and third trimesters due to fetal renal dysgenesis and oligohydramnios. If you have CKD and become pregnant, your blood pressure management will need to shift to labetalol, nifedipine, or methyldopa. Discuss this transition before conception if possible.

Postpartum. Cystatin C returns to pre-pregnancy values within six to eight weeks postpartum in women without underlying kidney disease. Postpartum thyroiditis, which affects 5 to 10 percent of women, can transiently alter Cystatin C through its effects on thyroid function; a Cystatin C checked in the context of unrecognized postpartum thyroiditis may be falsely elevated or low depending on the phase.

Who Should Get a Cystatin C Test

A Cystatin C measurement makes sense if any of the following apply:

• Your creatinine-based eGFR is between 45 and 75 mL/min/1.73 m² and a therapeutic decision (dose adjustment, nephrology referral, insurance coverage) depends on the exact GFR.
• You have low muscle mass, are underweight, or have been bedridden for extended periods.
• You are post-menopausal with multiple CKD risk factors and a creatinine that your clinician suspects is falsely reassuring.
• You have PCOS with hypertension, prediabetes, or both, and no baseline kidney assessment has been done.
• You have lupus, and your creatinine is stable but you want a more sensitive marker during disease surveillance.
• You are planning pregnancy and have known CKD or a history of preeclampsia.

Cystatin C is not a routine screening test for women without risk factors, and USPSTF does not currently recommend universal CKD screening. The test adds the most value when a decision genuinely turns on whether eGFR is 58 or 43 mL/min/1.73 m².

Timeline: When to Expect Cystatin C to Change

Changes in Cystatin C reflect changes in GFR or Cystatin C production rate. Here is a realistic expectation for common interventions:

| Intervention | Expected timeline for Cystatin C change | |---|---| | Normalizing TSH with levothyroxine | 6 to 12 weeks | | Stopping chronic NSAID use | 1 to 4 weeks | | Blood pressure control to target | 3 to 6 months | | SGLT2 inhibitor initiation | Acute rise at 2 weeks, then gradual stabilization | | Dietary sodium reduction | 4 to 8 weeks (via blood pressure) | | Structured aerobic exercise program | 12 to 24 weeks | | Anti-inflammatory therapy for lupus flare | 4 to 12 weeks |

Recheck Cystatin C no sooner than 90 days after making a significant change. Shorter intervals create noise without actionable signal, and the KDIGO chronicity criterion requires two measurements at least 90 days apart before diagnosing CKD.